Market Cap
$9.8B
KRYS
Krystal Biotech, Inc.
$322.28 ▼ -0.93%
Prev close $325.31Market cap$9.8B
ConsensusStrong Buy
12-mo target$392.11 (+21.7%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)36 New Institutional Positions14 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on KRYS right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (89%)
Inst. Holders
50 funds
Inst. Value
$9.0B
Inst. Activity
36 buys / 14 sells
Insider Activity
$0.00 buy / $26.6M sell
Insider Net $
-$26.6M
SEC Reports
10
Price chart 30d -13.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 14, 2026 Insider
Gangolli Julian S was granted 1,187 shares
Director
Sep 14, 2026 Insider
Gangolli Julian S was granted 471 shares
Director
Sep 14, 2026 Insider
JANNEY DANIEL was granted 1,187 shares
Director
Sep 9, 2026 ftd
Sep 4, 2026 SEC FTD: KRYS — 7,408 shares ($2.6M) failed to deliver
Settlement: 20260909, Price: $351.26, FTD Value: $2,602,134.08, KRYSTAL BIOTECH INC COM (USA)
Two top executives at Krystal Biotech (CEO Krish S. Krishnan and President of R&D Suma Krishnan) sold a combined ~$12.8M
CLUSTER — Impact 5/10
Director Dino A. Rossi filed a Form 144 notice of intent to sell 25,000 shares of Krystal Biotech common stock through G
144 — Impact 2/10
Krystal Biotech reported Q2 2026 VYJUVEK revenue of $119.2M (+24% YoY), slightly below the $121.0M consensus, with GAAP
8-K — Impact 6/10
Jun 30, 2026 Inst.
WILLIAM BLAIR INVESTMENT MANAGEMENT, — ADD
570,153 shares ($211.9M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
89% rate it Buy or better · 19 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 21, 2026 | B of A Securities | MAINTAIN | Buy | 54% |
| Aug 14, 2026 | RBC Capital | INITIATE | Outperform | 55% |
| Aug 4, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Jul 14, 2026 | B of A Securities | MAINTAIN | Buy | 54% |
| Jun 18, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| Jun 16, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jun 1, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 22, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 5, 2026 | Citigroup | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 10 | 2 | 0 | 0 | 89% | |
| Aug 1, 2026 | 7 | 9 | 2 | 0 | 0 | 89% | |
| Jul 1, 2026 | 7 | 9 | 2 | 0 | 0 | 89% | |
| Jun 1, 2026 | 7 | 9 | 2 | 0 | 0 | 89% | |
| May 1, 2026 | 7 | 9 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 7 | 9 | 2 | 0 | 0 | 89% | |
| Mar 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% |
Price targets
Where 9 covering analysts think KRYS trades over the next 12 months.
$392.11 +21.7% upside Strong Buy
Current$322.28 Low$284.00 Median$400.00 High$474.00 9 analysts
$284.00$474.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
10 SEC filing reports analyzed · 2 bullish, 1 bearish, 0 mixed, 7 neutral · avg impact 3.6/10.
BEARISHCLUSTER5/10
Two top executives at Krystal Biotech (CEO Krish S. Krishnan and President of R&D Suma Krishnan) sol
Sep 4, 2026
NEUTRAL1442/10
Director Dino A. Rossi filed a Form 144 notice of intent to sell 25,000 shares of Krystal Biotech co
Aug 14, 2026
BULLISH8-K6/10
Krystal Biotech reported Q2 2026 VYJUVEK revenue of $119.2M (+24% YoY), slightly below the $121.0M c
Aug 3, 2026
NEUTRALPRESS-RELEASE2/10
Krystal Biotech announced it will report Q2 2026 financial results on August 3, 2026. The filing con
Jul 23, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 9, 2026
ftd
FTD: KRYS — 7,408 shares ($2.6M) failed to deliver
Settlement: 20260909, Price: $351.26, FTD Value: $2,602,134.08, KRYSTAL BIOTECH INC COM (USA)
Sep 3, 2026
other
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate
Aug 14, 2026
ftd
FTD: KRYS — 1,767 shares ($0.6M) failed to deliver
Settlement: 20260814, Price: $328.34, FTD Value: $580,176.78, KRYSTAL BIOTECH INC COM (USA)
Aug 3, 2026
earnings
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch
Aug 3, 2026
earnings_calendar
KRYS Q2 2026 Earnings Before Market Open — 2026-08-03
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.00 | $1.60–$3.19 | -24.9% | +0.0% | 2↑ 3↓ | $0.1B | 10 |
| Next Q | $2.24 | $1.69–$3.41 | 31.5% | +0.0% | 2↑ 3↓ | $0.1B | 10 |
| Current FY | $7.87 | $6.98–$10.71 | 15.0% | +0.0% | 3↑ 5↓ | $0.5B | 11 |
| Next FY | $9.32 | $6.80–$12.04 | 18.5% | -0.8% | 3↑ 5↓ | $0.7B | 11 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $1.996 | — |
| 7d ago | $1.996 | — |
| 30d ago | $1.996 | — |
| 60d ago | $2.163 | -0.166 |
| 90d ago | $2.157 | -0.161 |
Institutional ownership
Which big funds own KRYS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $9.0B total value (24,228,579 shares) as of 2026-Q2. Top holders: NOMURA, FMR, BlackRock,. Net buying activity: 36 institutions added/increased vs 14 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| FMR LLC | 4,418,197 | $1.6B | 18.2% | — |
| BlackRock, Inc. | 4,181,432 | $1.6B | 17.3% | — |
| Avoro Capital Advisors LLC | 2,888,888 | $1.1B | 11.9% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,574,905 | $585.3M | 6.5% | — |
| STATE STREET CORP | 1,351,158 | $502.2M | 5.6% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,240,567 | $461.1M | 5.1% | — |
| Capital World Investors | 777,843 | $289.1M | 3.2% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 698,993 | $259.8M | 2.9% | — |
| Hood River Capital Management LLC | 663,375 | $246.6M | 2.7% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | ADD | 407,178 | 570,153 | +40.0% | $211.9M |
| GOLDMAN SACHS GROUP INC | ADD | 214,949 | 298,841 | +39.0% | $111.1M |
| NORGES BANK | NEW | — | 259,030 | — | $96.3M |
| 1832 Asset Management L.P. | DOUBLED | 42,600 | 99,300 | +133.1% | $36.9M |
| WESTFIELD CAPITAL MANAGEMENT CO LP | NEW | — | 98,707 | — | $36.7M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 9,600 | 59,680 | +521.7% | $22.2M |
| CITIGROUP INC | ADD | 31,172 | 56,016 | +79.7% | $20.8M |
| Russell Investments Group, Ltd. | DOUBLED | 26,210 | 52,621 | +100.8% | $19.6M |
| Allspring Global Investments Holdings, LLC | DOUBLED | 2,475 | 52,407 | +2017.5% | $19.5M |
| Neuberger Berman Group LLC | ADD | 33,084 | 51,876 | +56.8% | $19.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 50 transactions. Net -$26.6M — $0.00 bought, $26.6M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Gangolli Julian S | Director | AWARD | 1,187 | — | — |
| Sep 14, 2026 | Gangolli Julian S | Director | AWARD | 471 | — | — |
| Sep 14, 2026 | JANNEY DANIEL | Director | AWARD | 1,187 | — | — |
| Sep 14, 2026 | Mason Christopher | Director | AWARD | 1,187 | — | — |
| Sep 14, 2026 | JANNEY DANIEL | Director | AWARD | 471 | — | — |
| Sep 14, 2026 | Mason Christopher | Director | AWARD | 471 | — | — |
| Sep 14, 2026 | Sutherland Everett Rand | Director | AWARD | 471 | — | — |
| Sep 14, 2026 | Mazzacco Catherine | Director | AWARD | 1,187 | — | — |
| Sep 14, 2026 | Mazzacco Catherine | Director | AWARD | 471 | — | — |
| Sep 14, 2026 | Sutherland Everett Rand | Director | AWARD | 1,187 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for KRYS.
Shares short
3,163,642
Settlement Sep 15, 2026
Change vs prior
-5.5%
Semi-monthly cycle
Days to cover
13.2
At avg daily volume
Of shares outstanding
≈10.7%
Estimate — not % of float
All KRYS filing & press-release reports (10)
- CLUSTER reportSep 4, 2026
- 144 reportAug 14, 2026
- 8-K reportAug 3, 2026
- PRESS-RELEASE reportJul 23, 2026
- CLUSTER reportJun 5, 2026
- PRESS-RELEASE reportMay 4, 2026
- PRESS-RELEASE reportApr 21, 2026
- DEFA14A reportApr 3, 2026
- CLUSTER reportMar 6, 2026
- CLUSTER reportMar 3, 2026